PCSK9 inhibitor combo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a cholesterol-lowering drug (PCSK9 inhibitor) combined with standard treatments for advanced colorectal cancer that has spread or cannot be removed by surgery. It may help your body fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread or cannot be fully removed by surgery.
- Your cancer is a type called pMMR/MSS (you can ask your doctor to check).
- Your tumor shows high levels of a protein called PCSK9 (a test can tell).
- You are generally well enough to care for yourself (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new approach for advanced low rectal cancer. You'll receive a combination of chemotherapy, immunotherapy, and radiation before surgery, which may help shrink the tumor and make surgery easier.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial tests a new combination for locally advanced rectal cancer: adding a cholesterol-lowering drug plus an immunotherapy drug to the standard chemotherapy and radiation before surgery. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests a combination of focused radiation (SBRT), chemotherapy (CAPEOX), and two targeted drugs (bevacizumab and an immunotherapy) for colorectal cancer that has spread and can't be removed by surgery. The goal is to see if this combination can shrink tumors and help you live longer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.